reducing car t-cell therapy barriers for relapsed/refractory myeloma
Published 7 months ago • 17 plays • Length 4:04Download video MP4
Download video MP3
Similar videos
-
3:20
what treatments are there for myeloma patients who relapse after car t?
-
4:17
car-t cell therapy cilta-cel for relapsed/refractory myeloma | doris hansen, md | asco 2023
-
3:47
what is car t-cell therapy?
-
4:23
current and emerging car t-cell therapies for myeloma
-
4:28
evolving myeloma treatment options | car t-cell therapy
-
34:45
relapsed/refractory multiple myeloma and car t-cell therapy: navigating the patient journey
-
2:34
what is car t-cell therapy for myeloma?
-
5:23
updates on hbi0101, a car t-cell therapy, for r/r multiple myeloma
-
3:18
navigating myeloma car t-cell relapse: patient next steps
-
1:49
how can myeloma patients access car t-cell therapy clinical trials?
-
2:00
the value of car-t cell therapy for the treatment of r/r multiple myeloma
-
2:13
which myeloma patients are candidates for car t-cell therapy?
-
2:23
improving car t-cell therapy for myeloma
-
2:18
car t-cell therapy | care and monitoring post-treatment
-
5:15
planning for car t-cell therapy | advice for myeloma patients
-
3:52
is car t-cell therapy being used to treat newly diagnosed multiple myeloma?
-
6:58
gprc5d-targeted car t-cell therapy for rrmm: phase 1 study outcomes of bms-986393 (cc-95266)
-
4:21
phase 1 study phe885 bcma-directed car-t cell therapy for rrmm | adam sperling, md, phd | asco 2023
-
5:57
car t-cell therapy | what are potential complications?